Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. 2010

Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Anagawa, Inage-ku, Japan.

BACKGROUND Malignant mesothelioma is a highly aggressive form of cancer. Curative surgery is the only effective therapy for mesothelioma, and therefore early diagnosis is important. However, early diagnosis is difficult using current diagnostic imaging techniques, and a new imaging method for early diagnosis is urgently required. We evaluated the affinity of radiolabeled monoclonal antibodies to the C-terminal fragment of ERC/mesothelin for this purpose. METHODS In-labeled or I-labeled IgG against C-terminal fragment of ERC and its Fab fragment were evaluated in vitro by cell binding, competitive inhibition, and cellular internalization assays, and in vivo by biodistribution in mice bearing ERC-expressing tumors. Next, the Fab fragment was labeled with the positron emitter Cu and evaluated by positron emission tomography (PET). RESULTS Radiolabeled IgG and Fab showed specific binding to ERC-expressing mesothelioma cells with high affinity. Both radiolabeled IgG and Fab internalized into cells after binding to ERC on the cell surface. In-labeled IgG accumulated in ERC-expressing tumors and resulted in a moderate tumor-to-blood ratio at 4 days after injection. Furthermore, PET using Cu-labeled Fab visualized the tumor at 6 h after injection. CONCLUSIONS Cu-labeled Fab can be useful for ERC-specific PET imaging, and can thus facilitate improved diagnosis of patients with early-stage mesothelioma.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007140 Immunoglobulin Fab Fragments Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fab Fragment,Fab Fragments,Ig Fab Fragments,Immunoglobulins, Fab Fragment,Fab Immunoglobulin Fragments,Immunoglobulin Fab Fragment,Immunoglobulins, Fab,Fab Fragment Immunoglobulins,Fab Fragment, Immunoglobulin,Fab Fragments, Immunoglobulin,Fragment Immunoglobulins, Fab,Fragment, Fab,Immunoglobulin Fragments, Fab
D007205 Indium Radioisotopes Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes. Radioisotopes, Indium
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008654 Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) Mesotheliomas
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D003301 Copper Radioisotopes Unstable isotopes of copper that decay or disintegrate emitting radiation. Cu atoms with atomic weights 58-62, 64, and 66-68 are radioactive copper isotopes. Radioisotopes, Copper
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal

Related Publications

Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
July 2013, Molecular pharmaceutics,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
October 2016, Oncotarget,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
March 2011, Biomaterials,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
January 2011, PloS one,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
November 2017, Nuclear medicine and biology,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
October 2014, Neuroscience bulletin,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
January 2015, Hellenic journal of nuclear medicine,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
March 2020, Journal of nanoscience and nanotechnology,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
August 2018, Cancer biotherapy & radiopharmaceuticals,
Chisato Yoshida, and Chizuru Sogawa, and Atsushi B Tsuji, and Hitomi Sudo, and Aya Sugyo, and Tomoya Uehara, and Okio Hino, and Yukie Yoshii, and Yasuhisa Fujibayashi, and Toshimitsu Fukumura, and Mitsuru Koizumi, and Yasushi Arano, and Tsuneo Saga
August 2013, Bioconjugate chemistry,
Copied contents to your clipboard!